Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRT-232 (Navtemadlin) + TL-895 in Relapsed/Refractory Myelofibrosis
NCT04640532Phase 2Unknown
- Sponsor
- Kartos Therapeutics
- Start
- Nov 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of navtemadlin, TL-895 in myelofibrosis (MF), sponsored by Kartos Therapeutics. Status: unknown.
02
Drugs
navtemadlinTL-895
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04640532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04640532.